Please assess the completion status of the following clinical trial:

Trial Title: Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~1. Age \>18 years~2. Histologically confirmed diagnosis of DLBCL, not otherwise specified (NOS)~3. Tumor tissue for retrospective central pathology review and correlative studies must be provided.~4. At least one bidimensionally measurable, PET positive disease site (greatest transverse diameter of ≥1.5 cm, greatest perpendicular diameter of ≥1.0 cm)~5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2~6. International Prognostic Index (IPI) status of 2 to 5~7. Appropriate candidate for R-CHOP~8. Left ventricular ejection fraction (LVEF) of ≥50% assessed by echocardiography or cardiac multi-gated acquisition (MUGA) scan~9. Adequate hematologic, liver and renal function~10. Females of childbearing potential (FCBP) must:~    * not be pregnant~   * refrain from breast feeding and donating oocyte~   * agree to ongoing pregnancy testing~   * commit to continued abstinence from heterosexual intercourse, or agree to use and be able to comply with the use of double-barrier contraception~11. Males must:~    * use an effective barrier method of contraception if sexually active with FCBP~   * refrain from donating sperm~12. In the opinion of investigator, the patient must be able and willing to receive adequate prophylaxis and/or therapy for thromboembolic events~Major Exclusion Criteria:~1. Any other histological type of lymphoma according to World Health Organization (WHO) 2016 classification of lymphoid neoplasms, known double- or triple-hit lymphoma~2. Transformed non-Hodgkin lymphoma (NHL) and/or evidence of composite lymphoma~3. History of radiation therapy to ≥25% of the bone marrow or history of anthracycline therapy~4. History of prior non-hematologic malignancy except for the following:~   * Malignancy treated with curative intent and with no evidence of active disease present for more than 2 years before screening~  * Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled non-melanomatous skin cancer~  * Adequately treated carcinoma in situ without current evidence of disease~5. History of myocardial infarction ≤6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening arrhythmias~6. Patients with:~   * positive test results for active hepatitis B and C~  * known seropositive for or history of active viral infection with human immunodeficiency virus (HIV)~  * known active bacterial, viral, fungal, mycobacterial, or other infection at screening~  * known central nervous system (CNS) lymphoma involvement~  * history or evidence of clinically significant cardiovascular, CNS and/or other systemic disease that would in the investigator opinion preclude participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Tafasitamab in addition to R-CHOP
- Arm B (Type: EXPERIMENTAL): Tafasitamab plus lenalidomide in addition to R-CHOP

Based on this trial design, predict the completion outcome and termination type (if applicable).